ARTICLE | Management Tracks
Plus: Sage downsizes and updates from Xaira, DNA Script, Renovaro, Achieve, Adverum and more
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
October 18, 2024 12:40 AM UTC
BenevolentAI S.A. (Euronext:BAI) announced the departure of CEO Joerg Moeller and the appointment of Kenneth Mulvany as executive chairman, with Chairman Peter Allen becoming deputy chairman. The AI drug discovery company also named Michael Brennan chief strategy and financial officer, and executive director. Mulvany, chair of the company until 2021, and Brennan co-founded BenevolentAI in 2013.
Moeller took over as CEO in January from acting CEO François Nader, who had been filling in following the departure of CEO Joanna Shields in September 2023. Another shake-up to the C-suite occurred in July, when CFO Catherine Isted left the biotech following a board review that sought to bolster operational efficiency and the company’s strategic focus. Other board changes announced Thursday include the departures of Jean Raby and John Orloff. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653909/co-founders-mulvaney-brennan-return-to-benevolentai-as-ceo-moeller-departs